ASTRO 2024指南对乳腺癌患者部分乳腺照射资格的影响(KROG 24-01)
本研究纳入2019年3家三级医疗中心收治的pTis-T2N0乳腺癌患者,按ASTRO 2017与2024指南分类评估部分乳腺照射(PBI)资格。浸润性癌785例中,符合PBI比例从2017版「适合」19.2%升至2024版「强烈推荐」42.4%;导管原位癌286例中从27.3%升至51.7%。年龄标准从50岁放宽至40岁及取消清晰切缘要求是主要驱动因素。
要点
- 浸润性乳腺癌PBI资格从2017版19.2%升至2024版42.4%。
- 导管原位癌PBI资格从2017版27.3%升至2024版51.7%。
- 年龄标准放宽与取消清晰切缘要求是资格扩大的关键因素。
核心结论
- ASTRO 2024指南使浸润性乳腺癌和导管原位癌的PBI资格均大幅增加。
- 这些发现提示PBI使用可能增加,为早期乳腺癌提供个体化优化治疗选择。
研究设计与样本
- 研究纳入2019年3家三级医疗中心诊断为pTis-T2N0乳腺癌的患者。
- 所有患者接受保乳手术联合放射治疗的标准治疗。
- 随后按ASTRO 2017和2024指南对患者进行分类。
主要发现
- 浸润性乳腺癌785例中192例接受PBI。
- 浸润性癌按ASTRO 2017指南19.2%归为「适合」,按2024指南42.4%归为「强烈推荐」。
- 导管原位癌286例中50例(17.5%)接受PBI。
- 导管原位癌PBI资格从2017指南27.3%升至2024指南51.7%,近乎翻倍。
- 年龄标准从50岁扩至40岁及取消清晰切缘要求是浸润性癌和导管原位癌资格大幅增加的关键因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The American Society for Radiation Oncology (ASTRO) has recently published new guidelines for the eligibility for partial breast irradiation (PBI). This study aims to evaluate the eligibility rates of PBI according to the ASTRO 2017 and 2024 guidelines. METHODS AND MATERIALS: Patients diagnosed with pTis-T2N0 breast cancer in 2019 from 3 tertiary medical centers were accrued. All patients received standard treatment consisting of breast-conserving surgery followed by radiation therapy. Subsequently, patients were classified according to the ASTRO 2017 and 2024 guidelines. RESULTS: For invasive breast cancer, 785 patients were included, among whom 192 received PBI. Classification according to the ASTRO guidelines showed a substantial increase in the proportion of patients eligible for PBI: 19.2% were classified as "suitable" under the ASTRO 2017 guidelines, while 42.4% were classified as "strongly recommended" under the ASTRO 2024 guidelines. Among 286 patients diagnosed with ductal carcinoma in situ (DCIS), 50 (17.5%) received PBI. The proportion of PBI-eligible patients nearly doubled, from 27.3% under the ASTRO 2017 guidelines to 51.7% under the ASTRO 2024 guidelines. The expanded age criterion from 50 to 40 years and the removal of the clear resection margin requirement were key factors contributing to this substantial increase in both invasive breast cancer and DCIS. CONCLUSIONS: The eligibility for PBI has dramatically increased for both invasive breast cancer and DCIS under the ASTRO 2024 guidelines. These findings suggest a potential for increased use of PBI, offering individualized and optimized treatment options in early breast cancer.
引用
- Chun SJ, Park S, Kim YB, et al. Impact of the ASTRO 2024 Guideline on Partial Breast Irradiation Eligibility in Breast Cancer Patients (KROG 24-01). Pract Radiat Oncol. 2024. PMID: 39667667. doi:10.1016/j.prro.2024.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。